Advanced glycation end products among patients maintained on antipsychotics

Int Clin Psychopharmacol. 2017 Sep;32(5):256-261. doi: 10.1097/YIC.0000000000000179.

Abstract

The aim of this study was to measure advanced glycation end products (AGEs) among participants maintained on antipsychotics using the AGE Reader and to compare them with controls from the general population. Participants maintained on antipsychotics for at least 6 months were recruited from the Psychiatry Department at Rumailah Hospital, Doha, Qatar. Healthy controls were recruited from the primary healthcare centers in Doha, Qatar. AGEs of a total of 86 participants (48 patients and 38 controls) were recorded. Among the group maintained on antipsychotics, women, smokers, and Arabs had significantly higher AGEs levels compared with men, nonsmokers, and non-Arabs, respectively (P<0.05). The levels of AGEs were higher among the group of patients maintained on antipsychotics in comparison to controls; however, the difference did not reach statistical significance. This is the first study to examine AGEs in patients maintained on antipsychotics. Our findings showed that such patients do not differ significantly from controls comparing AGEs levels. Future investigations might need to consider recruiting a larger sample size using a prospective design.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antipsychotic Agents / adverse effects*
  • Case-Control Studies
  • Cross-Sectional Studies
  • Female
  • Glycation End Products, Advanced / metabolism*
  • Humans
  • Male
  • Middle Aged
  • Risk Factors
  • Skin / drug effects*
  • Skin / metabolism*
  • Young Adult

Substances

  • Antipsychotic Agents
  • Glycation End Products, Advanced